Description FDA Finalizes Guidance Reviews for Cancer Clinical Trials

The US Food and Drug Administration (FDA) on Wednesday finalized guidance on an optional streamlined submission process for determining the risk of an investigational in vitro diagnostic (IVD) in a clinical trial where an investigational IVD is being co-developed with an oncology investigational drug.

Read More: https://lnkd.in/fHUKHvV

https://bit.ly/35XGStw